{"name":"Laboratorios Goulart S.A.","slug":"laboratorios-goulart-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Taro Elixir","genericName":"Taro Elixir","slug":"taro-elixir","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"oxytetracycline, taro elixir","genericName":"oxytetracycline, taro elixir","slug":"oxytetracycline-taro-elixir","indication":"Respiratory tract infections","status":"phase_3"}]}],"pipeline":[{"name":"Taro Elixir","genericName":"Taro Elixir","slug":"taro-elixir","phase":"phase_3","mechanism":"Taro Elixir's mechanism of action is not publicly available.","indications":[],"catalyst":""},{"name":"oxytetracycline, taro elixir","genericName":"oxytetracycline, taro elixir","slug":"oxytetracycline-taro-elixir","phase":"phase_3","mechanism":"Oxytetracycline is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit.","indications":["Respiratory tract infections","Skin infections","Gastrointestinal infections"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}